Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Ratios

Nu-Med Plus (NUMD) Capital Expenditures (2018)

Nu-Med Plus' Capital Expenditures history spans 4 years, with the latest figure at $1.0 for Q4 2018.

On a quarterly basis, Capital Expenditures changed N/A to $1.0 in Q4 2018 year-over-year; TTM through Dec 2019 was $1.0, a 0.0% change, with the full-year FY2018 number at -$5025.0, changed N/A from a year prior.
Capital Expenditures hit $1.0 in Q4 2018 for Nu-Med Plus, up from -$1101.0 in the prior quarter.
Over the last five years, Capital Expenditures for NUMD hit a ceiling of $1.0 in Q4 2018 and a floor of -$1101.0 in Q4 2014.